GuidelinesOther guideline
Cardiac Therapy
Minoxidil Angiotensin receptor blockers (ARBs) Atorvastatin - high dose (80mg/day) Ezetimibe ATC Code C02DC01 Medicine Minoxidil Indication Severe hypertension not responding to other drugs NEMLC Recommendation Approved Review Indicators n/a Date Ratified 20 September 2007 ATC Code C09CA Medicine Angiotensin receptor blockers (ARBs) Indication Add on therapy in cardiac failur
Angiotensin receptor blockers (ARBs)
Atorvastatin - high dose (80mg/day)
| ATC Code | C02DC01 |
| Medicine | Minoxidil |
| Indication | Severe hypertension not responding to other drugs |
| NEMLC Recommendation | Approved |
| Review Indicators | n/a |
| Date Ratified | 20 September 2007 |
| ATC Code | C09CA |
| Medicine | Angiotensin receptor blockers (ARBs) |
| Indication | Add on therapy in cardiac failure on patients already on standard treatment including ACE-inhibitors, ß-Blockers and spironolactone |
| NEMLC Recommendation | Not Approved |
| Review Indicators | - New efficacy data from large RCT indicating larger benefit of adding ARBs to standard therapy - Decrease in price of ARBs so as to be similarly priced to ACE inhibitors |
| Date Ratified | 20 September 2007 |
| ATC Code | C09CA |
| Medicine | Angiotensin receptor blockers (ARBs) |
| Indication | As add on therapy in proteinuric nephropathies in patients already using an ACE-inhibitor |
| NEMLC Recommendation | Not Approved Insufficient evidence to support its use |
| Review Indicators | - New evidence indicating benefit in the form of a RCT of sufficient size with maximal doses of ACE-inhibitor used - New safety concerns - Decrease in price so as to be similarly priced to ACE-inhibitors |
|
Date Ratified |
20 September 2007 |
| ATC Code | C10AA05 |
| Medicine | Atorvastatin - high dose (80mg/day) |
| Indication | Familial hypercholesterolemia |
| NEMLC Recommendation | Approved For patients within the lipid clinic setting |
| Review Indicators | n/a |
|
Date Ratified |
31 March 2022 |
| ATC Code | C10AX09 |
| Medicine | Ezetimibe |
| Indication | Familial hypercholesterolemia |
| NEMLC Recommendation | Approved In combination with high-intensity or maximally tolerated therapy statin therapy |
| Review Indicators | n/a |
| Date Ratified | 20 October 2022 |